Skip to main content

Foghorn Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

FHTX$2.04+9.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I.FINANCIAL INFORMATION2
Item 1.Financial Statements (Unaudited)2
Condensed Consolidated Balance Sheets2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)3
Condensed Consolidated Statements of Stockholders’ Deficit4
Condensed Consolidated Statements of Cash Flows6
Notes to Unaudited Condensed Consolidated Financial Statements7
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20
Item 3.Quantitative and Qualitative Disclosures About Market Risk28
Item 4.Controls and Procedures28
PART II.OTHER INFORMATION29
Item 1.Legal Proceedings29
Item 1A.Risk Factors29
Item 5.Other Information29
Item 6.Exhibits30
Signatures31

i

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:

the initiation, timing, progress, enrollment, results, and timing of results and regulatory filings of our research and development programs and our preclinical studies;

our ability to advance any product candidates that we may develop and to successfully complete preclinical and clinical studies;

our ability to leverage our initial programs to develop additional product candidates using our platform;

developments related to our competitors and our industry;

our ability to expand the target populations of our programs and the availability of patients for clinical testing;

our ability to obtain regulatory approval for any future product candidates from the U.S. Food and Drug Administration (the “FDA”) and other regulatory authorities;

our ability to identify and enter into future license agreements and collaborations;

our ability to continue to rely on our contract development and manufacturing organizations (“CDMOs”) or contract research organizations (“CROs”), including those located outside the United States, such as those located in China, for our manufacturing and research needs;

statutory and regulatory developments in the United States and foreign countries, especially in China, including China’s Anti-Foreign Sanctions Law and its implementing regulations;

general economic conditions, including recessionary conditions, interest rates, monetary fluctuations and supply chain constraints;

ongoing and potential geopolitical instability and armed conflicts;

our ability to attract and retain key scientific and management personnel; and

the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our current and future product candidates, and our platform.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.